PDF
Full
Outline
To analyze the treatment enrollment status and influencing factors for rifampicin-resistant pulmonary tuberculosis patients in Guizhou Province, providing a basis for improving prevention and control strategies.
Based on case data, drug resistance screening records, and information on drug-resistant patients in Guizhou Province from 2016 to 2023, the enrollment rate (%) of rifampicin-resistant patients was described to characterize their distribution. Chi-square tests and binary logistic regression models were employed to analyze influencing factors.
The average annual enrollment rate for rifampicin-resistant pulmonary tuberculosis patients in Guizhou Province from 2016 to 2023 was 56.00%, increasing from 35.71% in 2016 to 88.20% in 2023 (trend χ2=729.839, P<0.001). An upward trend was observed across gender, age groups (<20 years, 20-39 years, 40-59 years, and ≥60 years), and nine municipalities (P<0.05 for all). Analysis of influencing factors indicated that compared to patients who were <20 years old, local, new cases, those with reports from designated multidrug-resistant tuberculosis hospitals, and those without diagnosis delays, the following were identified as risk factors for treatment enrollment: age ≥60 years (OR=0.471, 95%CI: 0.296-0.750), migrant status (OR=0.503, 95%CI: 0.391-0.646), initial treatment positive at 2/3 months (OR=0.676, 95%CI: 0.464-0.983), reports from general tuberculosis hospitals (OR=0.080,95%CI: 0.063-0.102) and from the disease control center (OR=0.048, 95%CI: 0.040-0.057), and diagnosis delays (OR=0.551,95%CI: 0.048-0.648) (P<0.05 for all).
The treatment enrollment status of rifampicin-resistant pulmonary tuberculosis patients in Guizhou Province has gradually improved, but continued attention is necessary. It is recommended to strengthen interventions for key populations, including those aged ≥60 years, migrants, initial treatment positive at 2/3 months, patients with reports from non-multidrug-resistant designated tuberculosis hospitals, and those experiencing diagnosis delays, to further enhance treatment enrollment rates.
PDF
68
28
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
